Sofusa is designed to be flexible because the demands of disease never are.

Disease Agnostic

In preclinical models, the Sofusa platform has demonstrated potential across a wide range of diseases by successfully delivering both small and large molecules without reformulation.

Drug Adaptability

The Sofusa platform has demonstrated the ability to deliver drugs transdermally across a wide range of molecule sizes, volumes and viscosities.

Patient Centered Design

The core Sofusa platform technology has been integrated into different device designs tailored to meet the needs of patients across various disease areas, from acute migraine, to rheumatoid arthritis, to cancer.

Product Development Pipeline

We are focused on development of novel biotherapeutics.

Name Indication Preclinical Phase I/II (PK) Pivotal/Phase III FDA Approval
Sofusa® DoseDisc system (anti-TNFα) Autoimmune
Sofusa® DoseConnect in Immune Oncology Various
Name Indication Phase
Sofusa® DoseDisc system (anti-TNFα) Autoimmune Phase I/II
Sofusa® DoseConnect in Immune Oncology Various Preclinical

©2018 Sofusa. All Rights Reserved.   |   Terms of Use   |   Privacy Policy